Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
Genentech ’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer
Research and Markets: PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer
BioTime Appoints Franklin Berger to Board of Directors
Correction to FDA Medication Errors Warning Story
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
Research and Markets: Systemic Lupus Erythematosus - Pipeline Review, H1 2013
Veteran growth manager Richie Freeman on the bright prospects for biotechnology, LED lighting, flash memory, and the outlook for energy in light of the Gulf oil spill.
The five biotech ETFs have very different portfolios with markedly different performance.